- Home
- MYGN vs CCBG Comparison
MYGN vs CCBG Comparison
Compare MYGN & CCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CCBG
- Stock Information
- Founded
- MYGN 1991
- CCBG 1895
- Country
- MYGN United States
- CCBG United States
- Employees
- MYGN N/A
- CCBG N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CCBG Major Banks
- Sector
- MYGN Health Care
- CCBG Finance
- Exchange
- MYGN Nasdaq
- CCBG Nasdaq
- Market Cap
- MYGN 642.0M
- CCBG 712.5M
- IPO Year
- MYGN 1995
- CCBG N/A
- Fundamental
- Price
- MYGN $7.96
- CCBG $42.98
- Analyst Decision
- MYGN Hold
- CCBG Buy
- Analyst Count
- MYGN 13
- CCBG 1
- Target Price
- MYGN $13.50
- CCBG $45.00
- AVG Volume (30 Days)
- MYGN 1.5M
- CCBG 58.9K
- Earning Date
- MYGN 11-06-2025
- CCBG 10-24-2025
- Dividend Yield
- MYGN N/A
- CCBG 2.23%
- EPS Growth
- MYGN N/A
- CCBG 14.00
- EPS
- MYGN N/A
- CCBG 3.42
- Revenue
- MYGN $832,900,000.00
- CCBG $240,944,000.00
- Revenue This Year
- MYGN $0.17
- CCBG $11.91
- Revenue Next Year
- MYGN $6.19
- CCBG $3.57
- P/E Ratio
- MYGN N/A
- CCBG $12.59
- Revenue Growth
- MYGN 3.83
- CCBG 8.96
- 52 Week Low
- MYGN $3.76
- CCBG $32.38
- 52 Week High
- MYGN $26.60
- CCBG $44.69
- Technical
- Relative Strength Index (RSI)
- MYGN 57.10
- CCBG 54.81
- Support Level
- MYGN $7.04
- CCBG $41.15
- Resistance Level
- MYGN $8.25
- CCBG $41.94
- Average True Range (ATR)
- MYGN 0.38
- CCBG 0.79
- MACD
- MYGN -0.06
- CCBG -0.11
- Stochastic Oscillator
- MYGN 54.77
- CCBG 49.56
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.